Evidence and unresolved questions in pulmonary hypertension: Insights from the 5th French Pulmonary Hypertension Network Meeting
- PMID: 38972109
- DOI: 10.1016/j.resmer.2024.101123
Evidence and unresolved questions in pulmonary hypertension: Insights from the 5th French Pulmonary Hypertension Network Meeting
Abstract
Pulmonary hypertension (PH) continues to present significant challenges to the medical community, both in terms of diagnosis and treatment. The advent of the updated 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) guidelines has introduced pivotal changes that reflect the rapidly advancing understanding of this complex disease. These changes include a revised definition of PH, updates to the classification system, and treatment algorithm. While these guidelines offer a critical framework for the management of PH, they have also sparked new discussions and questions. The 5th French Pulmonary Hypertension Network Meeting (Le Kremlin-Bicêtre, France, 2023), addressed these emergent questions and fostering a deeper understanding of the disease's multifaceted nature. These discussions were not limited to theoretical advancements but extended into the practical realms of patient management, highlighting the challenges and opportunities in applying the latest guidelines to clinical practice.
Keywords: Classification; Definition; Guidelines; Hemodynamics; Pulmonary hypertension.
Copyright © 2024 SPLF and Elsevier Masson SAS. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: BOUCLY Athénaïs reports a relationship with Grupo Ferrer Internacional SA that includes: board membership, consulting or advisory, and speaking and lecture fees. BOUCLY Athénaïs reports a relationship with Merck Sharp & Dohme UK Ltd that includes: board membership, consulting or advisory, funding grants, and speaking and lecture fees. BOUCLY Athénaïs reports a relationship with Astra Zeneca that includes: speaking and lecture fees. BOUCLY Athénaïs reports a relationship with AOP Orphan that includes: board membership, consulting or advisory, and speaking and lecture fees. BOUCLY Athénaïs reports a relationship with Janssen Pharmaceuticals Inc that includes: speaking and lecture fees. BERTOLETTI Laurent reports a relationship with MSD that includes: board membership, consulting or advisory, and speaking and lectures fees. BERTOLETTI Laurent reports a relationship with PFIZER/BMS that includes: board membership, and speaking and lectures fees. BERTOLETTI Laurent reports a relationship with LEO-Pharma that includes: board membership, consulting or advisory, and speaking and lectures fees. BERTOLETTI Laurent reports a relationship with VIATRIS that includes: consulting or advisory, and speaking and lectures fees. BERTOLETTI Laurent reports a relationship with BAYER that includes: board membership. FAUVEL Charles reports a relationship with Pfizer that includes funding grants. Fauvel Charles reports a relationship with Novartis that includes funding grants. Fauvel Charles reports a relationship with Boehringer Ingelheim Ltd that includes speaking and lecture fees. Fauvel Charles reports a relationship with Astra Zeneca that includes speaking and lecture fees. Fauvel Charles reports a relationship with Janssen Pharmaceuticals Inc that includes: consulting or advisory. GALLANT DEWAVRIN Mélanie reports no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. GERGES Christian reports a relationship with Grupo Ferrer Internacional SA that includes: speaking and lecture fees. Gerges Christian reports a relationship with AOPHealth that includes: speaking and lecture fees. Gerges Christian reports a relationship with OrphaCare that includes: funding grants. GRYNBLAT Julien reports no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. GUIGNABERT Christophe reports a relationship with Acceleron Pharma (Cambridge, MA, USA), a wholly-owned subsidiary of Merck & Co., Inc. (Rahway, NJ, USA) that includes: one funding grant outside the submitted work. Guignabert Christophe a relationship with Merck Sharp & Dohme UK Ltd that includes: one funding grants outside the submitted work and speaking and lecture fees. Guignabert Christophe a relationship with Corteria pharmaceutical that includes: one funding grant outside the submitted work. Guignabert Christophe a relationship with Structure therapeutics (ex ShouTi) that includes: one funding grant outside the submitted work. HASCOET Sébastien reports a relationship with Société Française de Cardiologie that includes: board membership, research grants. HASCOET Sébastien reports a relationship with Fédération Francaise de Cardiologie that includes: research grants. HASCOET Sébastien reports a relationship with Edwards Lifesciences that includes: consulting or advisory, and research grant. HASCOET Sébastien reports a relationship with Abbott vascular that includes: consulting or advisory, and research grant. None of these relationships influence the work reported in this paper. JAIS Xavier reports a relationship with MSD that includes: board membership, consulting or advisory, funding grants, and speaking and lecture fees. Jais Xavier reports a relationship with Janssen Pharmaceuticals Inc that includes: board membership, funding grants, and speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. JUTANT Etienne-Marie reports a relationship with Merck Sharp & Dohme UK Ltd that includes: consulting or advisory, speaking and lecture fees. Jutant Etienne-Marie reports a relationship with Chiesi Pharmaceuticals Inc that includes: speaking and lecture fees. Jutant Etienne-Marie reports a relationship with GlaxoSmithKline Inc that includes: speaking and lecture fees. Jutant Etienne-Marie reports a relationship with Janssen Pharmaceuticals Inc that includes: speaking and lecture fees. Jutant Etienne-Marie reports a relationship with AstraZeneca that includes: speaking and lecture fees. LAMBLIN Nicolas reports no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. MEYRIGNAC Olivier reports a relationship with Boehringer Ingelheim Ltd that includes: board membership, consulting or advisory, and speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. RIOU Marianne reports a relationship with Grupo Ferrer Internacional SA that includes: board membership. RIOU Marianne reports a relationship with MSD France that includes board membership and speaking and lecture fees. RIOU Marianne reports a relationship with Boehringer Ingelheim Ltd that includes: board membership and speaking and lecture fees. RIOU Marianne reports a relationship with Chiesi Pharmaceuticals Inc that includes: speaking and lecture fees. RIOU Marianne reports a relationship with Janssen Pharmaceuticals Inc that includes: speaking and lecture fees. RIOU Marianne reports a relationship with Menarini that includes: speaking and lecture fees. SAVALE Laurent reports a relationship with Merck Sharp & Dohme UK Ltd that includes: board membership, funding grants, and speaking and lecture fees. SAVALE Laurent reports a relationship with GlaxoSmithKline Inc that includes: speaking and lecture fees. SAVALE Laurent reports a relationship with Janssen Pharmaceuticals Inc that includes: speaking and lecture fees. TROMEUR Cécile reports a relationship with Merck Sharp & Dohme: board membership, consulting or advisory, and speaking and lecture fees. Tromeur Cécile reports a relationship with UK Ltd that includes: board membership, consulting or advisory, funding grants, and speaking and lecture fees. Tromeur Cécile reports a relationship with Chiesi Pharmaceuticals Inc that includes: speaking and lecture fees. Tromeur Cécile reports a relationship with GlaxoSmithKline Inc that includes: speaking and lecture fees. Tromeur Cécile reports a relationship with Janssen Pharmaceuticals Inc that includes: speaking and lecture fees. TURQUIER Ségolène reports a relationship with Grupo Ferrer Internacional SA that includes: board membership, consulting or advisory. TURQUIER Ségolène reports a relationship with Janssen Pharmaceuticals Inc that includes: speaking and lecture fees. VALENTIN Simon reports no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. SIMONNEAU Gerald reports a relationship with Grupo Ferrer Internacional SA that includes: board membership, consulting or advisory, and speaking and lecture fees. Montani David reports a relationship with Merck Sharp & Dohme UK Ltd that includes: board membership, consulting or advisory, funding grants, and speaking and lecture fees. Montani David reports a relationship with Boehringer Ingelheim Ltd that includes: board membership, consulting or advisory, and speaking and lecture fees. Montani David reports a relationship with Chiesi Pharmaceuticals Inc that includes: speaking and lecture fees. Montani David reports a relationship with GlaxoSmithKline Inc that includes: speaking and lecture fees. Montani David reports a relationship with Janssen Pharmaceuticals Inc that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. HUMBERT Marc reports a relationship with 35 Pharma that includes: consulting or advisory fees. Humbert Marc reports a relationship with Aerovate that includes: board membership, consulting or advisory fees. Humbert Marc reports a relationship with AOP Pharma that includes: board membership, consulting or advisory fees, speaking and lecture fees, funding grants. Humbert Marc reports a relationship with Bayer that includes: speaking and lecture fees. Humbert Marc reports a relationship with Chiesi Pharmaceuticals Inc that includes: board membership, consulting or advisory fees. Humbert Marc reports a relationship with Grupo Ferrer Internacional SA that includes: board membership, consulting or advisory, and speaking and lecture fees. Humbert Marc reports a relationship with Janssen that includes: board membership, consulting or advisory, and speaking and lecture fees. Humbert Marc reports a relationship with Keros that includes: board membership, consulting or advisory, funding grants, and speaking and lecture fees. Humbert Marc reports a relationship with United Therapeutics that includes: board membership, consulting or advisory. Olivier SITBON reports relationships with pharmaceutical companies including Aerovate, Altavant, AOP Orphan, Gossamer Bio, Ferrer, Janssen, Liquidia, Merck, Respira Therapeutics, Roivant and United Therapeutics. In addition to being investigator in clinical trials involving these companies, relationships include board membership, consulting or advisory, and speaking and lecture fees. In addition, Dr Sitbon's institution received funding grants from AOP Orphan, Gossamer Bio, Ferrer, Janssen and Merck. MONTANI David reports a relationship with Grupo Ferrer Internacional SA that includes: board membership, consulting or advisory, and speaking and lecture fees. Montani David reports a relationship with Merck Sharp & Dohme UK Ltd that includes: board membership, consulting or advisory, funding grants, and speaking and lecture fees. Montani David reports a relationship with Boehringer Ingelheim Ltd that includes: board membership, consulting or advisory, and speaking and lecture fees. Montani David reports a relationship with Chiesi Pharmaceuticals Inc that includes: speaking and lecture fees. Montani David reports a relationship with GlaxoSmithKline Inc that includes: speaking and lecture fees. Montani David reports a relationship with Janssen Pharmaceuticals Inc that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
